Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PYX-106 |
Synonyms | |
Therapy Description |
PYX-106 (BSI-060T) is an antibody that targets Siglec-15, potentially resulting in increased T cell proliferation and cytokine release and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 5522). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PYX-106 | PYX 106|PYX106|BSI-060T|BSI 060T|BSI060T | PYX-106 (BSI-060T) is an antibody that targets Siglec-15, potentially resulting in increased T cell proliferation and cytokine release and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 5522). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |